Background-There is a scarcity of long-term data from large-scale drug-eluting stent registries with a large enough sample to evaluate low-frequency events such as stent thrombosis (ST). Methods and Results-Five-year outcomes were evaluated in 12 812 consecutive patients undergoing sirolimus-eluting stent (SES) implantation in the j-Cypher registry. Cumulative incidence of definite ST was low (30 day, 0.3%; 1 year, 0.6%; and 5 years, 1.6%). However, late and very late ST continued to occur without attenuation up to 5 years after sirolimus-eluting stent implantation (0.26%/y). Cumulative incidence of target lesion revascularization within the first year was low (7.3%). However, late target lesion revascularization beyond 1 year also continued to occur without attenuation up to 5 years (2.2%/y). Independent risk factors of ST were completely different according to the timing of ST onset, suggesting the presence of different pathophysiological mechanisms of ST according to the timing of ST onset: acute coronary syndrome and target of proximal left anterior descending coronary artery for early ST; side-branch stenting, diabetes mellitus, and end-stage renal disease with or without hemodialysis for late ST; and current smoking and total stent length Ͼ28 mm for very late ST. Independent risk factors of late target lesion revascularization beyond 1 year were generally similar to those risk factors identified for early target lesion revascularization. Conclusion-Late adverse events such as very late ST and late target lesion revascularization are continuous hazards, lasting at least up to 5 years after implantation of the first-generation drug-eluting stents (sirolimus-eluting stents), which should be the targets for developing improved coronary stents. (Circulation. 2012;125:584-591.)
widely in clinical practice. Results from several randomized, controlled trials and registries comparing midterm (2-3 years) outcome between bare metal stents (BMS) and DES are generally reassuring for DES use with a marked reduction of target lesion revascularization (TLR) without major safety issues. 1, 2 However, in contrast to the clinical course after BMS implantation, 3 late adverse events such as very late stent thrombosis (VLST) and late TLR are reported to continue occurring beyond 1 year up to 3 to 4 years after DES implantation. 4, 5 Despite lingering concerns about DES-related late adverse events, there is a scarcity of longer-term data from large-scale DES registries with adequate statistical power to evaluate lowfrequency events such as stent thrombosis (ST). tation in a large observational database in a real-world clinical practice in Japan.
Methods

Study Population
The j-Cypher registry is a physician-initiated, prospective, multicenter observational study in Japan enrolling consecutive patients undergoing SES implantation. The design, enrollment status, and 2-year follow-up results were previously reported in detail. 6 From August 2004 to November 2006, 12 824 consecutive patients undergoing an attempt of at least 1 SES implantation were enrolled in the registry. After exclusion of 2 patients with procedural failure, 4 patients without stent use, and 6 patients with BMS use only, the study population consisted of 12 812 patients treated with at least 1 SES (19 662 lesions; Figures I and II in the online-only Data Supplement). The relevant review boards in all 37 participating centers (Appendix A in the online-only Data Supplement) approved the study protocol. Written informed consent was obtained from all patients.
Collection of 5-year follow-up information was conducted mainly through review of inpatient and outpatient hospital charts by the site investigators or experienced research coordinators in the independent research organization (Research Institute for Production Development, Kyoto, Japan; Appendix B in the online-only Data Supplement). Additional follow-up information was collected through contact with patients, relatives, or referring physicians by mailing a questionnaire on vital status, additional hospitalizations, and status of antiplatelet therapy. Telephone calls to patients were also conducted in several centers. Patients who were lost to follow-up were censored on the last day with follow-up information. When death, myocardial infarction (MI), and ST were reported, the events were adjudicated by use of the original source documents by an clinical events committee (Appendix C in the online-only Data Supplement). Adjudication of TLR events was left to the judgment of the site investigators. Median follow-up interval for the surviving patients was 1699 days (interquartile range, 1184 -1928 days). Clinical follow-up was completed in 12 540 patients (98%) at 1 year, in 11 839 patients (92%) at 2 years, and in 10 667 patients (83%) at 3 years. Five-year clinical follow-up was completed in 4301 patients (77%) among 5563 patients eligible for 5-year follow-up.
End Points and Definitions
Death was regarded as cardiac in origin unless obvious noncardiac causes could be identified. Any death during the index hospitalization was regarded as cardiac death. Sudden death was defined as unexplained death in previously stable patients. MI was adjudicated according to the definition in the Arterial Revascularization Therapy Study. 7 ST was defined according to the Academic Research Consortium definition. 8 Unless otherwise noted, definite ST in SES-treated lesions assessed on a patient basis was used as the end point for ST. TLR was defined as either percutaneous coronary intervention or coronary artery bypass grafting surgery resulting from restenosis or thrombosis of the SES-treated target lesion that included the proximal and distal edge segments and the ostium of the side branches. ST and TLR were counted on a patient basis. Events related to non-SES-treated lesions were not included in the evaluation of ST and TLR but were included in the evaluation of MI and any coronary revascularization. Stroke during follow-up was defined as ischemic or hemorrhagic stroke requiring hospitalization with symptoms lasting Ͼ24 hours.
Antiplatelet Therapy
The recommended antiplatelet regimen was aspirin (Ն81 mg daily) indefinitely and thienopyridine (200 mg ticlopidine or 75 mg clopidogrel daily) for at least 3 months. Duration of antiplatelet therapy was left to the discretion of each attending physician. Status of antiplatelet therapy was evaluated throughout the follow-up period as previously described. 6 Persistent discontinuation of thienopyridine was defined as withdrawal lasting at least 2 months. ESRD indicates end-stage renal disease; STEMI, ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; LAD, left anterior descending coronary artery; and LMCA, left main coronary artery. There were missing values in 4 patients for body mass index, in 7 patients for in-stent restenosis, in 25 patients for chronic total occlusion, in 10 patients for side-branch stenting, in 1698 patients for ejection fraction, in 236 patients for reference vessel diameter pre, in 5 patients for total stent length per patient, and in 51 patients for use of intravascular ultrasound.
*Variables used for multivariable analyses evaluating independent risk factors for stent thrombosis and target lesion revascularization.
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Statistical Analysis
Categorical variables are expressed as number and percentages. Continuous variables are expressed as meanϮSD unless otherwise indicated. Cumulative incidences were calculated by the Kaplan-Meier method, and differences were assessed with the log-rank test.
As a result of a potential competing risk issue, cumulative incidence estimates of definite ST and TLR accounting for competing mortality were also calculated. 9 Consistent with our previous report, 6 a Cox proportional hazard model was used to identify independent risk factors of ST (early, late, and very late) and TLR (within the first year and beyond 1 year). We used the 23 variables listed in Table 1 as potential independent variables. Multivessel stenting included in the previous report was excluded because of its significant correlation with total stent length Ͼ28 mm. 6 We did not include treatment of multiple lesions as a potential independent variable, also because of its significant correlation with total stent length Ͼ28 mm. We adjusted for the center effect by using center as a stratification variable. The continuous variables were dichotomized by clinically meaningful reference values or median values. To determine the independent risk factors, we first selected variables with values of PϽ0.05 in the univariate Cox models, and we confirmed that proportional hazard assumptions were acceptable on the plots of log (time) versus log [Ϫlog (survival)] stratified by the variables. We then included them simultaneously in the multivariable models and obtained the adjusted hazard ratios and their 95% confidence intervals. We imputed the missing values of potential independent variables in the multivariable analysis. In terms of the method for imputation, missing values for the categorical variables were regarded as absent, and missing values for the continuous variables were assigned to the dominant group after dichotomization of the continuous variables. Missing values for variables such as in-stent restenosis, chronic total occlusion, and use of intravascular ultrasound were regarded as absent. Missing values for reference vessel diameter pre Ͻ2.5 mm were regarded as absent, whereas missing values for body mass index Ͻ25.0 kg/m 2 and total stent length per patient Ͼ28 mm were regarded as present. In evaluating risk factors for late and very late ST, we included only those patients who completed the 30-day and 1-year follow-up without ST, respectively. Similarly, eligible patients for risk factor analysis for TLR beyond 1 year were those patients who completed the 1-year follow-up without TLR.
All statistical analyses were performed by a physician (T. K.) and a statistician (T. Morimoto) using JMP 8.0 and SAS 9.2 (SAS Institute Inc, Cary, NC). All reported P values were 2 sided, and values of PϽ0.05 were regarded as statistically significant.
Results
Baseline Characteristics
The study population reflected the real-world clinical practice in Japan, including large proportions of patients with advanced age, diabetes mellitus, prior percutaneous coronary intervention, multivessel disease, small-vessel disease, multivessel stenting, and intravascular ultrasound use and significant proportions of patients with end-stage renal disease, prior stroke, prior heart failure, target of in-stent restenosis, and target of chronic total occlusion. The prevalence of acute coronary syndrome was relatively low (Tables 1 and 2 ).
Clinical Outcome Through 5 Years
Cumulative incidence of all-cause death was 14.4% at 5 years after SES implantation (Table 3 and Figure 1A) . Cardiac death and sudden death constituted 47% and 16% of all-cause LAD indicates left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right coronary artery; and LMCA, left main coronary artery. There were missing values in 13 lesions for in-stent restenosis, in 42 lesions for chronic total occlusion, in 11 lesions for bifurcation lesion, in 10 lesions for side-branch stenting, in 407 lesions for lesion length, in 364 lesions for reference vessel diameter pre, in 100 lesions for use of intravascular ultrasound, in 81 lesions for postdilatation, in 245 lesions for maximum inflation pressure, in 41 lesions in length of stents used per lesion, and in 42 lesions for minimal stent size. death, respectively. The annual incidences of sudden death remained constant beyond 1 month after SES implantation through 5 years (0.49%/y; Figure 1A ). Cumulative incidence of definite ST was low (30 day, 0.3%; 1 year, 0.6%; and 5 years, 1.6%). However, late ST and VLST continued to occur constantly without attenuation up to 5 years after SES implantation (0.26%/y; Table 3 and Figure  1B ). Incidence estimates of definite ST accounting for com-peting risk were quite similar to the crude cumulative incidences presented above (30 day, 0.3%; 1 year, 0.5%; and 5 years, 1.5%). Among 172 ST events through 5 years (early, 44 events; late, 26 events; and very late, 102 events), 151 events (88%) resulted in MI. ST was the cause of MI during follow-up in 37% of 410 MI episodes. Regarding the status of antiplatelet therapy at the time of ST, the proportion of patients on dual antiplatelet therapy decreased with time 
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(early ST, 89%; late ST, 54%; and VLST, 32%). It was noteworthy that 27% of patients with late ST and 13% of patients with VLST had discontinued both aspirin and thienopyridine before the onset of ST ( Table I in the online-only Data Supplement). The cumulative incidence of TLR within the first year was relatively low (7.3%) with a high rate (61%) of angiographic follow-up within the first year. However, late TLR beyond 1 year also continued to occur constantly without attenuation up to 5 years after SES implantation (2.2%/y; Table 3 and Figure 1C ). The cumulative incidence of TLR at 5 years was 15.9%. Incidence estimates of TLR accounting for competing mortality were also similar to the crude cumulative incidences presented above (1 year, 7.2%; 5 years, 15.0%). The cumulative incidence of non-TLR at 5 years was also high (31.2%) with a constant rate of 3.8%/y beyond 1 year (Table  3 and Figure 2D ).
In terms of the status of antiplatelet therapy, the cumulative incidence of persistent discontinuation of thienopyridine was 25.1% at 6 months, 37.0% at 1 year, and 56.1% at 5 years after index SES implantation (Figure 2 ).
Risk Factors of ST According to the Timing of ST Onset
Independent risk factors of ST were completely different according to the timing of ST onset (Table 4 and Tables II-IV in the online-only Data Supplement): acute coronary syndrome and target of proximal left anterior descending coronary artery lesions for early ST; side-branch stenting, diabetes mellitus, and end-stage renal disease with or without hemodialysis for late ST; and current smoking at the time of the index procedure and total stent length Ͼ28 mm for VLST.
Risk Factors of Early and Late TLR
Independent risk factors of early TLR within 1 year included hemodialysis, side-branch stenting, total stent length Ͼ28 mm, prior coronary artery bypass grafting, target of in-stent restenosis, diabetes mellitus, target of chronic total occlusion, and reference vessel diameter pre Ͻ2.5 mm (Table  4 and Table VI in the online-only Data Supplement). Independent risk factors of late TLR beyond 1 year were generally similar to those risk factors identified for early TLR, including hemodialysis, total stent length Ͼ28 mm, reference vessel (Table 4 and Table  VI in the online-only Data Supplement).
Discussion
The main findings of the current analysis were the following. First, late adverse events such as VLST and late TLR continue to occur beyond 1 year after SES implantation without attenuation of their annual incidences up to 5 years. Second, risk factors of ST were markedly different according to the timing of ST onset, whereas risk factors of late TLR were similar to those of early TLR within 1 year. Long-term follow-up studies up to 5 years from several randomized controlled trials comparing DES with BMS have demonstrated sustained benefit of DES without major safety concerns. 10 -13 However, clinical and coronary anatomic characteristics of patients enrolled in these trials are markedly different from the characteristics of patients treated in daily clinical practice. Furthermore, none of these trials had adequate power to evaluate rare clinical events such as ST. There is a scarcity of data regarding long-term outcomes from large-scale all-comers DES registries. The Bern/Rotterdam 2-center registry reported persistent occurrence of late ST and VLST in up to 4 years of follow-up with the slope of the cumulative incidence curve of 0.53%/y. 4 However, in that report, the number of patients at risk beyond 2-year follow-up was very limited. Our present 5-year follow-up results from a very large all-comers registry clearly demonstrated that VLST was the continuous hazard, lasting at least up to 5 years after SES implantation without any signal of attenuation, although the annual incidence of ST in this cohort was relatively low (0.26%/y).
The risk factors for late ST and VLST have not been fully elucidated. The risk factors identified for late ST and VLST in the present analysis were consistent with the characteristics of patients with late ST and VLST illustrated in the Registry of Stent Thrombosis for Review and Reevaluation (RESTART), which was a Japanese nationwide registry of patients with ST of SES. 14 Time-dependent differences in the risk factors of ST could suggest presence of different pathophysiological mechanisms of ST according to the timing of ST onset. Furthermore, we could identify only 2 independent risk factors with modest effect sizes for VLST, namely current smoking and long total stent length, highlighting the difficulty in developing a clinically relevant risk stratification model for VLST.
In the present analysis, late TLR beyond 1 year also continued to occur constantly without attenuation up to 5 years after SES implantation with the annual incidence of 2.2%/y. Persistent occurrence of late TLR up to 5 years was in sharp contrast to the time course of TLR after BMS implantation. 3 Although randomized, controlled trials comparing DES with BMS demonstrated sustained efficacy of DES with lower rate of TLR through 5 years, we should closely examine additional late catch-up beyond 5 years. The mechanisms of late restenosis of DES are currently very poorly understood, although inflammatory reactions, de novo atherosclerosis, and mural thrombus formation might be playing roles. Similarities in the risk factors of early and late TLR might suggest that lesions with relatively greater early neointimal hyperplasia in the complex lesions might be prone to significant late restenosis requiring TLR.
VLST and late TLR are clearly the ongoing late adverse events associated with the use of SES (a first-generation DES). Because we have not yet observed attenuation of the annual incidences of VLST and late TLR at 5 years after SES implantation, we should continue to evaluate longer-term outcome beyond 5 years to fully estimate the magnitude of problems associated with use of SES. It has not yet been clarified whether prolonged dual antiplatelet therapy could decrease the incidences of VLST and late TLR. 15 VLST and late TLR, together with the residual risk for early TLR, clearly represent the unmet needs for coronary DES, which should be appropriately addressed by the future development of improved coronary stents.
Study Limitations
This study has several important limitations. First, patients participating in the registry were not fully monitored; therefore, underreporting of the adverse events was possible. In addition, the clinical follow-up rate beyond 3 years was far from complete, although the follow-up rate was much higher than that in the Bern/Rotterdam 2-center registry. However, the incidences of death and ST in the present registry were higher than those reported in the Japan Post-Marketing Surveillance Registry (J-PMS) study, which was a fully monitored, company-directed postmarket surveillance registry of 2000 patients undergoing SES implantation in Japan. 16 Therefore, it seems unlikely that the low ST rate in this study is due to underreporting of adverse events. Second, although we could not discriminate between clinically driven and angiographically driven TLR, the high rate of angiographic follow-up in the first year suggests that a significant proportion of TLR within the first year might be angiographically driven TLR. Furthermore, the relatively high rate of TLR beyond 1 year might be due to scheduled follow-up angiography conducted according to local protocols in some centers. Third, the number of ST events was not large enough to compare variables that affect risks differently in different time periods, although the present study is the largest study evaluating 5-year outcome of DES.
Conclusion
Late adverse events such as VLST and late TLR are continuous hazards at least up to 5 years after implantation of the first-generation DES (SES), which should be the targets in developing improved coronary stents.
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